Acrivon Therapeutics, Inc. Common Stock (ACRV) — Financial statements
Income statement, balance sheet, and cash flow for Acrivon Therapeutics, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 1↑34.8% | 1↑87.7% | 0.54 | 0.00 | 0.00 | |
| Gross Profit | -1↓34.8% | -1↓87.7% | -0.54 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 60↓6.3% | 64↑40.7% | 45↑89.9% | 24↑74.6% | 14 | |
| General & Administrative Expenses | 24↓4.3% | 25↑19.6% | 21↑142.1% | 9↑253.1% | 2 | |
| Selling & Marketing Expenses | 0.00 | 0.00↓100.0% | 0.13 | 0.00 | 0.00 | |
| SG&A Expenses | 24↓4.3% | 25↑18.8% | 21↑143.6% | 9↑253.1% | 2 | |
| Other Expenses | -1↓34.8% | -1 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 83↓6.2% | 88↑32.2% | 67↑104.2% | 33↑101.8% | 16 | |
| Total Costs & Expenses | 84↓5.7% | 89↑32.7% | 67↑105.9% | 33↑101.8% | 16 | |
| Operating Results | ||||||
| Operating Income | -84↑5.7% | -89↓32.7% | -67↓105.9% | -33↓101.8% | -16 | |
| Depreciation & Amortization | 1↑34.8% | 1↑87.7% | 0.54↑47.3% | 0.36↑883.8% | 0.04 | |
| EBITDA | -83↓4.0% | -80↓32.9% | -60↓85.3% | -32↓100.0% | -16 | |
| EBIT | -84↓4.4% | -81↓33.4% | -60↓84.9% | -33↓101.8% | -16 | |
| Interest & Other Income | ||||||
| Net Interest Income | 6↓29.6% | 9 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 6↓29.6% | 9 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -9↓26.2% | -7 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↓28.2% | 9↑26.2% | 7↑359.7% | 1↑2625.4% | -0.06 | |
| Income Before Tax | -78↑3.3% | -81↓33.4% | -60↓93.8% | -31↓91.9% | -16 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -78↑3.3% | -81↓33.4% | -60↓93.8% | -31↓91.9% | -16 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -78↑3.3% | -81↓33.4% | -60↓93.8% | -31↓91.9% | -16 | |
| Bottom-Line Net Income | -78↑3.3% | -81↓33.4% | -60↓93.8% | -31↓91.9% | -16 | |
| EPS (Basic) | -2.02↑3.8% | -2.10↑23.4% | -2.74↓93.0% | -1.42↓12.7% | -1.26 | |
| EPS (Diluted) | -2.02↑3.8% | -2.10↑23.4% | -2.74↓93.0% | -1.42↓12.7% | -1.26 | |
| Weighted Average Shares | 39↑0.6% | 38↑73.5% | 22↑0.7% | 22↑69.8% | 13 | |
| Weighted Average Diluted Shares | 39↑0.6% | 38↑73.5% | 22↑0.7% | 22↑69.8% | 13 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.